<DOC>
	<DOCNO>NCT00526149</DOCNO>
	<brief_summary>RATIONALE : BI 2536 may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study side effect well BI 2536 work treat patient recurrent metastatic solid tumor .</brief_summary>
	<brief_title>BI 2536 Treating Patients With Recurrent Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Investigate BI 2536 demonstrate antitumor activity select tumor type . - Further document safety profile treat patient population . - Describe plasma concentration time-course follow administration single administration BI 2536 patient different tumor type use appropriate population pharmacokinetic model . OUTLINE : This multicenter study . Patients receive BI 2536 IV 1 hour day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Blood collect periodically study . Plasma sample analyze pharmacokinetic study HPLC tandem mass spectrometry . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Tumorspecific criterion : Head neck cancer : Histologically cytologically proven squamous cell carcinoma head neck ( exclude nasopharyngeal primary ) Patients present new nonirradiated lesion preirradiated field target lesion eligible Recurrent metastatic disease , longer suitable local therapy Prior use chemotherapy/chemoradiotherapy/EGFR inhibitor treatment primary disease/nonmetastatic disease allow No prior chemotherapy recurrent metastatic disease Prior treatment EGFR inhibitor metastatic advance disease allow Breast cancer Histologically proven recurrent metastatic adenocarcinoma breast fail prior taxane anthracycline therapy Patient must minimum one line maximum 2 line chemotherapy treatment give either adjuvant treatment recurrence/metastatic disease Patients qualify Her2based therapy allow Hormone receptor status specify Ovarian cancer Histologically proven ovarian epithelial cancer Metastatic inoperable locally advanced disease Patients either progress relapse within 6 month completion line platinum taxanebased therapeutic regimen advance disease Soft tissue sarcoma Histologically proven advance and/or metastatic malignant soft tissue sarcoma high intermediate grade one follow histology define WHO classification 2002 : Leiomyosarcoma , adipocytic sarcoma , synovial sarcoma , others Fibroblastic ( adult fibrosarcoma , myxofibrosarcoma , sclerosing epithelioid fibrosarcoma ) Socalled fibrohistiocytic ( pleomorphic malignant fibrous histiocytoma [ MFH ] , giant cell `` MFH '' , inflammatory `` MFH '' ) Malignant glomus tumor Skeletal muscle ( rhabdomyosarcoma , alveolar pleomorphic ) exclude embryonic rhabdomyosarcoma Vascular ( epithelioid hemangioendothelioma , angiosarcoma ) Uncertain differentiation ( synovial , epithelioid , alveolar soft part , clear cell , desmoplastic small round cell , extrarenal rhabdoid , malignant mesenchymoma , perivascular epithelioid cell tumour [ PEComa ] , intimal sarcoma ) exclude chondrosarcoma , Ewing tumors/primitive neuroectodermal tumor ( PNET ) Malignant peripheral nerve sheath tumor Malignant solitary fibrous tumor Undifferentiated soft tissue sarcoma otherwise specify Other type sarcoma ( list eligible ) , approve Study Coordinator ( write email approval need prior registration ) Excluded follow : Embryonic rhabdomyosarcoma Chondrosarcoma Osteosarcoma Ewing tumors/primitive neuroectodermal tumor Gastrointestinal stromal tumor Dermatofibrosarcoma protuberans Inflammatory myofibroblastic sarcoma Neuroblastoma Malignant mesothelioma Mixed mesodermal tumor uterus Patients must receive one combination two single agent chemotherapy regimen advance disease treatment must include anthracycline medically contraindicate Melanoma Histologically proven metastatic malignant melanoma Ocular melanoma exclude Patients must either receive prior chemotherapy recurrent /metastatic disease receive one line chemotherapy pending LDH ≤ 2 time upper limit normal ( ULN ) One prior line immunotherapy allow General criterion : Measurable disease , define unidimensionally measurable base RECIST target lesion least 20 mm 10 mm measure spiral CT scan Documented progressive disease proven image prior study entry ( i.e. , progression document 2 imaging scan perform within past 6 month prior registration show progression accord RECIST ) No clinical evidence brain metastasis PATIENT CHARACTERISTICS : Male female Menopausal status specify ECOG performance status 02 ANC ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 9 mg/dL Serum creatinine ≤ 175 μmol/L Bilirubin ≤ 1.5 time ULN AST/ALT ≤ 2.5 time ULN ( 5 time ULN liver metastasis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment Absence psychological , familial , sociological , geographical factor would potentially hamper compliance study protocol followup schedule No previous active malignancy least 5 year exception conebiopsied carcinoma cervix adequately treat basal squamous cell skin carcinoma No concomitant intercurrent illnesses include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance trial requirement consider relevant evaluation efficacy safety trial drug PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since administration prior systemic treatment current malignancy include treatment chemotherapy , radiotherapy , immunotherapy , hormonal therapy , treatment monoclonal antibody , small molecule tyrosine kinase inhibitor others No persistence toxicities prior anticancer therapy deem clinically relevant No treatment investigational drug within past four week within less four halflife time investigational drug treatment trial drug ( whatever long period ) No major surgery within 4 week prior first treatment trial drug Concurrent treatment corticosteroid , include prednisone bisphosphonates , allow long treatment start entry study long dose stable two week prior enrollment present trial Palliative radiotherapy may give study bone pain reason due progressive disease ( e.g. , bronchial obstruction , ulcerate skin lesion ) The irradiated area limit involve 10 % bone marrow The irradiated area use tumor response assessment No concurrent investigational drug No concurrent antitumor therapy chemotherapy , hormone therapy , gene therapy , tyrosine kinase inhibitor , therapy monoclonal antibody immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult desmoplastic small round cell tumor</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
	<keyword>ovarian carcinosarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>